Anti-Obesity Drugs Market Size

Anti-Obesity Drugs Market Size

Anti-obesity Drugs Market size was valued at around USD 5.6 billion in 2023 and is estimated to grow at 27% CAGR from 2024 to 2032. Anti-obesity drugs are medications designed to aid in weight loss and obesity management by altering physiological processes related to appetite, metabolism, or nutrient absorption. These drugs may work through various mechanisms such as appetite suppression, inhibition of fat absorption, or increasing metabolism.

The global prevalence of obesity and related health issues has escalated significantly, prompting a demand for effective solutions beyond traditional diet and exercise. For instance, according to estimates, in February 2024, the worldwide incidence of obesity, characterized by a body mass index (BMI) equal to or exceeding 30 kg/m2, was projected to increase from 14% of the global population in 2020 to 25% by 2035, encompassing approximately 1.9 billion individuals. Additionally, advancements in medical research have elucidated the complex physiological mechanisms underlying obesity, providing insights into potential targets for pharmaceutical intervention. Moreover, societal factors such as sedentary lifestyles and easy access to calorie-dense foods have exacerbated the obesity epidemic, prompting a need for complementary medical interventions.
 

Furthermore, the recognition of obesity as a multifactorial condition influenced by genetic, environmental, and behavioral factors has underscored the importance of personalized treatment approaches, including pharmacovigilance, which was valued at USD 8.5 billion in 2022. The convergence of these drivers underscores the importance of anti-obesity drugs as part of a comprehensive strategy to address the complex challenge of obesity and its associated health risks.